Brief: Knight Therapeutics And Rigel Pharmaceuticals To Commercialize Fostamatinib In Latin America
24/05/2022 12:36
May 24 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS ENTERS INTO EXCLUSIVE LICENSE AND
SUPPLY
AGREEMENTS WITH RIGEL PHARMACEUTICALS TO COMMERCIALIZE
FOSTAMATINIB IN LATIN AMERICA
* KNIGHT THERAPEUTICS- RIGEL TO GET UPFRONT CASH PAYMENT,
WITH
POTENTIAL FOR ADDITIONAL REGULATORY,COMMERCIAL MILESTONES,
STEPPED-UP ROYALTIES
Source text for Eikon: ID:nGNX52RCB4
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil